Lightnews — Scholar-powered news

Reposted by Chrystal Paulos

Megen Wittling @megen-w.bsky.social · 14d

Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs!
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social

academic.oup.com/jimmunol/adv...

Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma

Abstract. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach, earning U.S. Food and Drug Administration approval in patients with anti–PD-

academic.oup.com

1 3

Reposted by Chrystal Paulos

More Perfect Union @moreperfectunion.bsky.social · Aug 29

The City of Atlanta is opening its first municipal grocery store today.

The city is spending $3.5 million in partnership with a neighborhood grocery chain in an effort to eliminate a downtown food desert.

www.wsbtv.com/news/local/a...

City of Atlanta opening grocery store to clear up downtown food desert

The Azalea Fresh Market opens on Friday.

www.wsbtv.com

210 1.9K 8.9K

Reposted by Chrystal Paulos

ivy @askylitocean.bsky.social · Aug 30

33 230 2.6K

Reposted by Chrystal Paulos

I Post Animal Vids... 😊 @realjfairclough.bsky.social · Aug 30

Baby goats are wild... 😍🤣

#bluesky #animals #babygoats

54 230 1.6K

Chrystal Paulos @chrystalpaulos.bsky.social · Aug 1

www.v.org/grants/chrys...
Honored to be awarded the All-Star V Foundation grant! Inspired by great team efforts between #Paulos and #Lesinski labs! Props to cell therapy gurus @megen-w.bsky.social #AnnaCole @meganmw.bsky.social and crew @winshipcancer.emory.edu

Chrystal Paulos, PhD - V Foundation

Melanoma is a serious and often deadly type of skin cancer. Although immunotherapy has saved many lives, it still doesn’t work for every patient. Our lab is developing ways to give the immune system a...

www.v.org

1 5

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

9/ 🙌 Huge thanks to our awesome team: Anna Cole (1st author), Hannah Knochelmann (co-1st), Megan Wyatt, @megen-w.bsky.social Megen Wittling, Natalie Horvat, Aubrey Smith, Guillermo Rangel Rivera, Sound Kumaresan, Pawel Muranski, Ayana Ruffin, Jeremy Boss, & MPI Greg Lesinski. #CancerImmunotherapy

1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

8/💡From cells to cures: @meganmw.bsky.social Megan Wyatt in our lab is developing a TIL-based therapy leveraging Th17 cells for checkpoint-refractory tumors.
Stay tuned @winshipcancer.emory.edu. Thanks to collaborations w/@lesinskilab.bsky.social and support @thevfoundation.bsky.social, NCI $ more!

1 2

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

7/ 🧠Why does this matter? Because T cell therapies often ignore B cells. Our data say: stop doing that.
CD4+ Th17 cells provide the help B cells need to generate potent antitumor antibodies. It’s a team sport.

1 1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

6/ 🔬IL-21 production by Th17 cells is essential. Block the IL-21 receptor and the B cell response crashes (Fig 7).
Reduced germinal centers. Less plasma cells. No sustained immunity. IL-21 is the handshake between these two arms.

1 1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

5/ 🧠Here’s the kicker: If we transfer serum from cured mice into naive mice, they resist metastatic challenge. Passive transfer of protection. See the lungs in Fig 8F + quant in 8G. The antibodies *work*.

1 1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

4/ 🧪Mice cured with Th17 therapy have tons of class-switched, tumor-binding antibodies in serum (IgG1, IgG2a, IgG2b). Shown in Fig 8A-C. Not just any antibody — it’s tumor-specific and persistent.

1 1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

3/ 💥 Depleting B cells with αCD20 or using muMT mice abolishes the effect of Th17 therapy. Survival plummets. B cells aren’t passengers here — they’re co-drivers of durable immunity.

1 1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

2/ 🐭Want to keep tumors away for good?
Check out this weeks @cp-cancercell.bsky.social
You’ll need both T cells *and* B cells.
Th17 therapy fails in mice genetically deficient in B cells or in mice antibody depleted of B cells.
Bottom line:No host T/B cells, no cure!
See survival curves (Fig 3).

1

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!

Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...

www.cell.com

1 13 29

Reposted by Chrystal Paulos

LesinskiLab @lesinskilab.bsky.social · Jul 3

Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!

pubmed.ncbi.nlm.nih.gov/40590857/

Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed

These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...

pubmed.ncbi.nlm.nih.gov

1 3 7

Chrystal Paulos @chrystalpaulos.bsky.social · Jun 6

Amazing talk by Dr. Ayana Ruffin @winship on the importance of CD2 in adoptive immunotherapy of cancer. It’s a T:B thing. #2025SIS on the UVA campus.

1

Chrystal Paulos @chrystalpaulos.bsky.social · May 15

Not a trend I will partake in. :/

The New York Times @nytimes.com · May 15

The latest drinking craze? Dropping a few jalapeño slices into a chilled glass of white wine.

Jalapeño Wine Delights TikTok but Confuses Bartenders

www.nytimes.com

Reposted by Chrystal Paulos

Lidia_FL @biolidia.bsky.social · May 12

This week I will be attending the @helloeacr.bsky.social conference, entitled "Defense is the Best Attack," where we'll catch up on the latest advances in immuno-oncology and advanced therapies. It's always a great opportunity to meet people and learn from the best. Hoping to meet you all there! 😁🧪

3 4

Chrystal Paulos @chrystalpaulos.bsky.social · May 13

Excited to present at the first Breast Center Translational Research Seminar Series @winshipcancer.emory.edu Thank Dr. Shipra Gandhi for the invite.

3

Chrystal Paulos @chrystalpaulos.bsky.social · May 9

www.biorxiv.org/content/10.1...

A systematic approach to analyze T cell migration: application to mouse melanoma tumors

T cells must assess and choose between surveilling large areas, but also engage efficiently with the target cells. This process is translated into variations in speed and turning angle of T cells. In ...

www.biorxiv.org

1

Chrystal Paulos @chrystalpaulos.bsky.social · May 9

www.biorxiv.org/content/10.1...

An Aged Microenvironment Increases CAR T Cell Cytotoxicity but Impairs Therapeutic Efficacy

Background Cancer disproportionately affects the elderly, who are often less able to tolerate traditional cytotoxic therapies, and may benefit from T cell–based immunotherapies. However, studies evalu...

www.biorxiv.org

Chrystal Paulos @chrystalpaulos.bsky.social · May 4

pubmed.ncbi.nlm.nih.gov/39585339/

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma - PubMed

Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting r...

pubmed.ncbi.nlm.nih.gov

1

Chrystal Paulos @chrystalpaulos.bsky.social · May 3

What is the most important unanswered questions to address in the field of cancer immunotherapy?

1

Chrystal Paulos @chrystalpaulos.bsky.social · Apr 28

Delighted to present our labs exciting work on T cell metabolism and cancer immunotherapy today at AACR by Guillermo Rangel Rivera and Soundharya Kumaresan!

1

Chrystal Paulos @chrystalpaulos.bsky.social · Apr 25

Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...

Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking

Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...

www.biorxiv.org

2 2